Share on StockTwits

Equities research analysts at JPMorgan Chase & Co. lifted their target price on shares of Merck & Co. (NYSE:MRK) from $60.00 to $64.00 in a research note issued to investors on Wednesday, American Banking & Market News reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 15.92% from the company’s current price.

MRK has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, May 1st. They now have a $61.00 price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Merck & Co. in a research note on Wednesday, April 30th. They now have a $64.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of Merck & Co. from $62.00 to $66.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $60.62.

Shares of Merck & Co. (NYSE:MRK) opened at 55.21 on Wednesday. Merck & Co. has a one year low of $44.62 and a one year high of $59.84. The stock has a 50-day moving average of $56.49 and a 200-day moving average of $52.5. The company has a market cap of $162.4 billion and a price-to-earnings ratio of 36.17. Merck & Co. also was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 32,443,294 shares, a growth of 13.0% from the March 31st total of 28,708,787 shares. Based on an average daily trading volume, of 11,401,160 shares, the short-interest ratio is presently 2.8 days. Currently, 1.1% of the shares of the company are sold short.

Merck & Co. (NYSE:MRK) last released its earnings data on Tuesday, April 29th. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.09. The company had revenue of $10.30 billion for the quarter, compared to the consensus estimate of $10.44 billion. During the same quarter last year, the company posted $0.85 earnings per share. Merck & Co.’s revenue was down 3.8% compared to the same quarter last year. Analysts expect that Merck & Co. will post $3.47 EPS for the current fiscal year.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.